RADX
Radiopharm Theranostics LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.99
P/S
2.27
EV/EBITDA
0.55
DCF Value
$-44.35
FCF Yield
-445.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
1.1%
Operating Margin
-1050.6%
Net Margin
-1055.3%
ROE
-105.2%
ROA
-44.3%
ROIC
-53.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2024 | $3.6M | $-38.3M | $-5.28 |
| FY 2023 | $299.2K | $-47.9M | $-36.00 |
| FY 2022 | $292.4K | $-34.6M | $-33.00 |
| FY 2021 | $8.8K | $-30.3M | $-29.76 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
AU
Exchange
NASDAQ
Beta
0.84
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.